Several aspects of the design were unique: 

• The study included autistic people with co-occurring conditions such as ADHD or intellectual disability who were previously often excluded from autism studies)  
• The study aimed to more accurately represent autistic females by recruiting autistic females to form one third of the autistic sample. See our LEAP leaflet for an overview of the project. 
• The study used the same core protocol in all participants (including appropriate adaptations for age and ability level).

Key scientific papers and findings
The large-scale data set of LEAP has allowed researchers to investigate previous reports of group differences between autistic and non-autistic people.  In a first step, we investigated group differences across all levels, including cognition, brain structure, function and tested some of the most influential theories of autism. This resulted in the replication of some findings, but also so-called null findings, which are equally important for furthering scientific understanding of autism. For example, we found average group differences in theory of mind, executive function and emotion processing (when tested behaviourally, but not in terms of underlying brain function). We replicated differences in brain structure with small effect sizes but did not find differences in EEG power bands (measure of specific brainwave frequency).

Overall, there was considerable overlap between autistic and non-autistic people in various cognitive and brain-related characteristics. We estimated that when statistical effects are moderate or even large, this translates to 48-70% of autistic people falling within the ‘typical range’, showing no difference or atypicality statistically.

These initial sets of findings prompted us to develop new methods and approaches to identify potential sub-groups among autistic people with specific cognitive or neurobiological characteristics.

Over 100 research papers, including the LEAP data collected as part of EU-AIMS and AIMS-2-TRIALS projects, have been published. Some examples of initial findings using data from the first and second assessment waves are included below, and other publications can be found on the AIMS-2-TRIALS publication page here.   

• Multiple types of data were collected in LEAP to look at the relationship between different measures, and how these differ in autistic and non-autistic people. Researchers found that when they combined information from multiple types of data in a multi-modal model, such as brain function during rest and while completing various tasks as well as measures of brain anatomy, they found substantially higher average differences between the autistic and non-autistic groups than when only single measures were compared. Within the autism group, individual differences in the multifunctional model were associated with cognitive and social but not non-social and functioning characteristics of autism. This shows that combinations of measures are more informative that any single measure at understanding differences in autistic people. More information can be found via this paper

• The timing of the N170, a pattern of brain activity measured using EEG (electroencephalography) and related to face processing, was identified as a potential ‘biomarker’ that may help to identify who will respond most to certain kinds of support strategy and prevent those unlikely to benefiting from starting with it in the first place. This measure provided a helpful way to identify subgroups of autistic people who shared similar social outcomes two years later. See this news piece for further information

• Cortical thickness of the brains of autistic and non-autistic people was examined using structural MRI scans.  The brain cortex is one of many indicators of brain anatomy, measuring cortical thickness is one method used to map a person’s brain structure and understand how this may be related to behaviour. Individual differences among autistic people based on this measure were identified and were found to be related to genetic likelihood for autism and sensory subgroups. 
  More information can be found via this paper

• Differences in functional connectivity patterns in the brain between the cerebellum and other brain areas were identified, including increased connectivity of the cerebellum with sensory and motor networks. This finding could explain multisensory and visual motor differences in autism. More information can be found via this paper

• Researchers investigated the influence of environmental and family conditions on mental health, with a particular focus on understanding internalising symptoms (such as anxiety and depression) and externalising symptoms (such as aggression and impulsive behaviours). This research included autistic people across a wide age range and across countries, using the LEAP and a South African cohort.  Participants with more autistic traits were found to experience more mental health challenges across countries. Furthermore, the “Family System” (family size, composition, maternal factors) consistently influenced mental health, but its specific impact varied. Across the LEAP cohort, the Family System had a protective effect against mental health symptoms; in South Africa, this relationship was reversed, with participants with larger families being more susceptible to experiencing mental health conditions, suggesting this may be impacted by the high/low-middle income setting. In both cases, autistic traits diminished these effects. These results reinforce the notion that context and autistic traits interact to influence mental health, and that the household support should be considered when providing support to autistic individuals, especially when considering regional differences in diagnosis and service availability. More information can be found via this paper 

• Researchers investigated the wellbeing of autistic children and adults in the LEAP cohort. Although well-being was on average lower for in the autism than the non-autistic group, a notable proportion (36%–71% across quality-of-life domains) of autistic individuals reported good well-being. Reduced wellbeing was related to depression symptoms, across all ages. For children and adolescents, anxiety and social-communication difficulties were also related to quality of life. The study suggests that support and services to improve mental health, especially depression, may also improve broader wellbeing and quality of life for autistic people. More information can be found via this paper: More information can be found via this paper

• Researchers identified a subgroup of autistic people who had difficulties with emotion recognition compared to the rest of the group. This was based on the combination of performance across three different tests. This subgroup had higher scores on measures of autistic characteristics, lower scores on measures of adaptive behaviour and showed brain functional differences. These findings suggest support in emotion recognition could be helpful for supporting social interaction in a subset of autistic individuals, if they wish to seek support. More information can be found via this paper.

For the latest updates on papers, including ones currently under review, see our publications page.  

Community collaborations and priorities

LEAP brought together different experts (e.g., clinicians, neuroscientists, biologists) to provide the necessary expertise to carry out this study and interpret the outcomes. AIMS-2-TRIALS’ collaboration with autism community members on projects using LEAP data has been an important part of the project and ensures community perspectives are incorporated in the research process (see A-Reps page for more details). This has also helped develop a template of how collaborative working with the community can be done in future work. An example of this work within LEAP is a research paper sharing the genetic findings from the study, which includes several community members as co-authors who were part of the data interpretation and write up of the paper. A pre-print of this paper can be found here.

Driven by community engagement and policy work in AIMS-2-TRALS, there has been a shift in focus of LEAP projects and papers toward sensory, mental health, developmental perspectives and further investigation of co-occurring epilepsy to reflect community priorities in these areas. This aligns with the priorities highlighted by the AIMS-2-TRIALS  A-Rep group and published work by our group and others (Cage et al. 2024, Ikhsan, Holt et al 2026).

Data analysis projects from LEAP have had an increased focus on mental health and the impact this has on quality of life of autistic people. To ensure community perspectives are incorporated in this work collaborations were set up on several mental health projects using LEAP data including researchers and autism community members. There has also been an increased focus on co-occurring ADHD in autistic people and the challenges associated with this condition, as a result of community prioritisation of this area of research. Lastly, new work building on the LEAP study, examining autistic burnout is being carried out in collaboration with autism community members.

This project has had greater focus on the variation within autism in our approaches and analysis techniques. This had included identifying subgroups of autistic people who differ in terms of biological characteristics such as genetics or brain structure or function and also differ in terms of behavioural characteristics. These groups likely differ in terms of the support they need and the how effective certain interventions might be. This provides steps towards a more personalised approach to autism both in terms of support and treatment approaches for those that want and need them. We are now in a position to trace developmental trajectories by combining the data from each volunteer across 3 time-points and over 8-12 years. This provides the critical basis to identify markers for the progression of specific clinical features, their combination, or changes in quality of life. 

Wider impacts from the project

LEAP researchers have developed and made methodological advances in research techniques such as normative modelling, which provide new ways of looking at variation within groups and development over time. This could allow researchers to make predictions about individuals which is a vital step towards being able to provide personalised interventions and support. This technique creates a reference model of development (for example of brain structure) and qualifies how much each individual differs from that model, or the statistical ‘norm’*. This method aims to better quantify statistically the variation within autism across development and therefore improve understanding of the diversity of autism. These techniques were not available at the beginning of the project and have required development to address the statistical questions required in this context. The statistical models and methodologies used are therefore an important resource for future work in this area.

Analysis techniques used in AIMS-2-TRIALS have given more consideration to the heterogeneity of autism, going beyond the historical focus on ‘case control’ differences (i.e., differences between autistic and non-autistic people, on average). This is important to help understand differences within groups of autistic people, and how these relate to diverse outcomes. This could, in the future, support the development of more personalised support for autistic people (including medical and non-medical approaches depending on a person’s preference and needs). These approaches include looking at subgroups or clusters within and across groups as well as normative modelling techniques which look at developmental trajectories. Modelling developmental trajectories can allow us to see and predict how people develop over time on different measures such as brain structure, performance on a particular task or clinical characteristics such as depression and anxiety or sensory sensitivity. This leads to better ways of mapping variation within autism as it shows the variation and helps identify any patterns within this that could in the future be useful for diagnosis, individualised support and interventions for those that want and need them.

Historically, autistic people with a co-occurring intellectual disability have been an under-researched group. LEAP includes unique data from a subgroup of autistic people with co-occurring mild to moderate intellectual disability which have been analysed and can be further utilised in the future to increase understanding about this group of autistic people. The data from LEAP can also be combined with other AIMS-2-TRIALS cohorts such as SynaG to increase statistical power and validate findings. SynaG included people with rare genetic conditions associated with autism and intellectual disability including Phelan McDermid syndrome and NRXN. 

More about this project can be found here via this website page

Researchers showed that a particular feature of EEG (electroencephalography) data in called N170, a brain response that reflects face processing, was different in autistic people and could be a potential biomarker of autism. These finding suggests a difference in the brain’s processing of faces in autistic people. More details can be found here. Following analysis and validation of the N170 biomarker using LEAP and data from other cohorts, AIMS-2-TRIALS embarked on a unique process to validate this marker with European Medicines Agency (EMA). This was the first work with a potential biomarker in the autism field to do this. See the news piece on this work for more details. Identification and further validation of biomarkers should allow for more effective research into autism, including interventions and support for core and co-occurring characteristics for those that seek them. 

LEAP data has significant potential to inform new and innovative methods and scientific progress in the future, including for the research community beyond AIMS-2-TRIALS. This is made possible via sustainable data sharing on the ELIXIR platform. The AIMS-2-TRIALS data sharing process has been designed in collaboration with autism community members to ensure that data would be shared in an ethical manner and following recommendations from the community. Data is only shared for participants that explicitly gave their consent to share data beyond the research consortium. Applications to access data are reviewed by the data access committee, including scientists and community members to ensure future projects are of a high quality and meet AIMS-2-TRIALS consortium principles.  This offers autism researchers beyond the project an opportunity to analyse data to address new research questions. This also opens up an opportunity for researchers combine different data types from the LEAP project, and with data from other projects (e.g. ABC-CT, InovAND, SFARI, POND) for the purposes of replication of findings. This provides greater validity of research findings.

See the data sharing FAQs and the ELIXIR platform for more information. 

Want to find out more?

See AIMS-2-TRIALS YouTube videos for more details on some of these topics, including the LEAP ‘Meet our researchers’, where our work on sensory, mental health, epilepsy and brain activity are discussed. The autistic burnout video explores our work with community members on this topic, and the LEAP Epilepsy video explores co-occurring autism and epilepsy, and the important inclusion of this work within LEAP.

For further information on the LEAP project, see the LEAP page here and the LEAP flyer here.

*this term is used in the context of statistical terminology not in reference to individual variation.

Dr Doherty, a consultant anaesthetist from Ireland who is autistic and has ADHD, is one of 28 individuals to receive this prestigious award at a ceremony at the Palace of Westminster on 23 July 2026. The award recognises her outstanding work championing the inclusion of neurodivergent professionals in healthcare and improving healthcare for autistic people.

In 2019, Mary founded Autistic Doctors International, which has grown into a global community of more than 1,500 autistic doctors, providing peer support, advocacy, research and education. She was also awarded a PhD, titled “Autistic doctors: leveraging insider perspectives to improve healthcare for autistic people”, and can be read here.

As a valued member of the AIMS-2-TRIALS A-Rep group, Mary brings her lived experience and expertise to help shape autism research alongside autistic people and carers from across Europe.

Congratulations to Dr Mary Doherty on this well-deserved recognition and thank you for your continued contribution to AIMS-2-TRIALS and the wider autism community.

.

AIMS-2-TRIALS has released the first dataset to the autism research community, marking a significant milestone for the project. This follows a collaborative effort between AIMS-2-TRIALS researchers and autism community members with the data sharing platform ELIXIR to develop data sharing plans, procedures and documentation to ensure ethical and data security due diligence. Researchers external to the AIMS-2-TRIALS consortium who wish to access the data may submit requests for consideration by the project review board.

This focus on collaborative development of data sharing plans with the community has not only led to practical solutions for data sharing but also a broader consideration and discussion on community priorities for ethical data sharing.

Dr Beth Oakley, Lecturer in Neurodevelopmental sciences and AIMS-2-TRIALS Scientific co-ordinator, said:  

‘It has been a privilege to learn from, and work with, AIMS-2-TRIALS A-Reps colleagues in launching AIMS-2-TRIALS data via ELIXIR Luxembourg. Data sharing, particularly in autism research, is an incredibly sensitive area. It has been of utmost importance to design a rigorous data access process that prioritises community concerns and preferences and is delivered to the highest ethical standards. This would not have been possible without community input.’

What data does this include?

This includes data from the first and second timepoints of the AIMS Longitudinal European Autism Project (LEAP). LEAP includes data from autistic and non-autistic children/young people and adults (6-30 years of age at the first timepoint) collected over approximately 4 years between 2014 and 2017. The data includes pre-processed or summary data from MRI, eye tracking, EEG, questionnaire data, coded interview data, cognitive task, and genetics data collected from research sites in the UK, the Netherlands and Germany.

More details on this project can be found on our website and in our ​​LEAP leaflet. 

Where is the data being hosted?

The AIMS-2-TRIALS external database is hosted on a platform called ELIXIR. ELIXIR’s own goal is to make life science data easier to find, share, put together, and analyse. ELIXIR (and its Luxembourg node, specifically) was selected as the best fit for hosting the AIMS-2-TRIALS external database, as it is an existing GDPR compliant European infrastructure for long-term sustainability of life sciences data. 

How can researchers apply for access to the data?

Researchers can apply for access to the data via ELIXIR’s platform by filling out a project proposal form including details of the requested measures, importance of the proposed project, planned statistics and data management plan and how the proposed research fits with the consortium’s ethical principles. Details of the application process can be found on the ELIXIR website.

How have we considered the ethics of data sharing and involved community perspectives?

It is vital that data sharing is carried out with due consideration of the ethics and privacy of research participants, as well as considering the implications for the wider autism community.  Steps have and will be taken to ensure these critical issues are addressed. This includes autism community consultation, development of data access policies and consortium principles, and a review committee with both scientific and community representation.

AIMS-2-TRIALS autistic representatives (A-Reps) have been involved in the planning process through a dedicated data sharing working group, including advising on key ethical considerations around data sharing, reviewing and editing our data sharing policies/procedures. A-Reps are a group of autistic people and parents/carers of autistic people who have worked with AIMS-2-TRIALS researchers across the course of the grant to consult and input into the project. Working with autism community members to develop our data sharing plans has been key to understanding and addressing issues of importance to the community surrounding these endeavours (e.g. unethical or unintended use, data security, biased data interpretation). More details on this process can be found in our FAQs.

Our A-Reps shared their experiences throughout this process:

‘Having A-Reps input on the data sharing plans and procedures via a dedicated data sharing working group has been essential to help ensure that ethical safeguards are implemented to protect autistic participant’s study data.’ 

Sarah Douglas, AIMS-2-TRIALS A-Rep 

‘Since the beginning of the project, the involvement of the A-reps has played an important role in shaping the direction of the work. This collaboration has helped ensure that the data sharing approach is practical, relevant, and built around the real needs of the autism community.’ 

How proposals will be reviewed?

For each external project proposal request that AIMS-2-TRIALS receives, the LEAP Project Review Committee will review to decide if the data can be shared. The review committee for project proposals includes A-Rep members and researchers from the AIMS-2-TRIALS consortium. Review by the committee will include a check that each project proposal is in line with the research themes that participants originally consented to. Reviewers will also consider the content of the proposal to ensure it meets the consortium’s ethical principles (Beneficence, Inclusion/Engagement, Culture/Language, Minimising Risk), as well as ensuring the scientific validity of projects.

What safeguards will be in place when researchers access the data?

Researchers applying for access to AIMS-2-TRIALS data will need to submit proof of ethics approvals (and/or relevant codes of conduct), a data management plan for their project proposal and consider the ethical implications of their project. Researchers who wish to access AIMS-2-TRIALS data will also need to confirm that they have read, understood, and acknowledged our data access policy/procedure.

AIMS-2-TRIALS data will only be shared in the manner participants have agreed to, including the sharing of data beyond the AIMS-2-TRIALS consortium. If participants wish to change their data sharing preferences, they are free to do so at any ​​​​time.  To protect participant privacy, secure identification codes were assigned to each individual’s data. All study assessments use these codes, rather than names or any other personal identifiers. The ELIXIR platform also uses two factor authentication for those accessing the data, as an additional layer of security.

Further information:

For more information on general data access, please see this website page: Data Sharing

For more information on data access if you are a researcher, please see this website page: Data Access for Researcher

For more information on data access if you were a participant, please see this website page: Data Access for Participant

For more information on the LEAP project, please see this website page: LEAP project page

Researchers from the University of Cambridge led a study investigating autistic people’s priorities for change in collaboration with colleagues in the AIMS-2-TRIALS consortium including autism community members and autism charity representatives across Europe.

Although globally autism diagnosis rates are on the rise and autism awareness is improving, autistic people and carers still face significant challenges in receiving the necessary services and going through their day-to-day life. It is vital that policies on autism strive to address these issues and meet the needs of the autism community more effectively.

The 10 Points for Change survey was distributed in multiple European languages and collected data from 1,709 autistic people, parents and careers of autistic people and members of autism-related organisations.

Image: A 2-page summary of these findings can be found here:www.aims-2-trials.eu/our-research/autism-policy-across-europe/

The paper for this study can be found here: https://link.springer.com/article/10.1186/s13229-026-00706-3 

On 24 February 2026, at the EURORDIS Black Pearl Awards ceremony in Brussels, the Company Award for Patient Engagement was presented to Roche and King’s College London (KCL) in recognition of their leadership of the AIMS-2-TRIALS project. The award was granted in recognition of the commitment of AIMS-2-TRIALS leaders to involving autistic people and people with rare genetic conditions, as equal partners in this initiative.

Harald Neerland, Autism Europe President, presented the award to Professor Emily Jones from King’s College London (KCL) and Birkbeck, University of London. Other representatives from KCL and Autism-Europe who attended the ceremony included Dr Bethany Oakley and Professor Tony Charman (KCL), and Aurélie Baranger (Autism-Europe).

Caption: Professor Emily Jones from King’s College London (KCL) and Birkbeck, University of London (right), receiving the award and Harald Neerland of Autism Europe (left), presenting the award.

Based on the nomination criteria, the award recognises organisations that demonstrate a long-term, constructive commitment to meaningful collaboration with participants across the full medicine development lifecycle. Awardees demonstrate sustained engagement with people with lived experience in key research and development decisions, supported by strong internal awareness, capability, and planning. The criteria also consider evidence of real impact, such as the integration of participant-informed outcomes, experiences, and priorities into decision-making.

EURORDIS commented:

“Not only is the project contributing to improving the health outcomes of underserved autistic communities, it is also exploring rare genetic conditions associated with autism, including Phelan-McDermid syndrome, Fragile X and SHANK-related disorders. The direct involvement from people living with autism and rare neurodevelopmental diseases across the entire project has led to a better understanding of shared biological pathways and to an improved infrastructure for clinical trials across Europe, benefiting communities previously underrepresented in research.

 

Embedded in genuine trust and collaboration, AIMS-2-TRIALS stands out as a best practice example where the input of participants with lived experience of autism has significantly shifted perspectives in conducting research, sharing data or developing meaningful outcome measures. EURORDIS commends the project leads for ensuring that the needs and priorities of autistic people, including those living with rare genetic conditions associated with autism, are appropriately represented in shaping the solutions that can improve their lives.”

Bethany Oakley from King’s College London, who attended the ceremony, said:

“A key highlight at this awards event was that it showcased the impact and momentum that can be built when many communities come together in support of a common goal. Diverse rare genetic conditions communities were represented, all agreeing on priorities such as the need for earlier and more efficient diagnosis, and post-diagnostic information and support, better targeted treatment options to be available to serve individual needs, and wider public acceptance”.

This achievement marks an important moment for the consortium as it enters the final year of the project. Congratulations to everyone involved in AIMS-2-TRIALS whose dedication has helped advance and improve meaningful participant engagement.

*The AIMS-2-TRIALS Communications Team acknowledge that preferred language in this context would be community engagement or participant engagement. We are unable to alter or change the name of this award.

The event ‘Towards a Common Approach for Autism in Europe’ was organised by Autism Europe in partnership with AIMS-2-TRIALS researchers. Autism-Europe hosted the event in collaboration with the Disability Intergroup (an informal group of Members of the European Parliament). The aim was to promote discussions among key stakeholders on the essential steps for advancing autism policy research and services. This includes improving the quality of life for autistic individuals and advocating for more equitable access to autism services and resources throughout the European Union (EU).

Researchers from the AIMS-2-TRIALS consortium, the world’s largest research project on autism, including the University of Cambridge, King’s College London, Birkbeck University of London, Hospital Universitario Gregorio Marañón in Madrid, and an autism community representative (A-Rep), shared key findings and learnings from the project and the implications this has for required policy changes and next steps. A-Reps are a group of autistic people and parents/ carers of autistic people that are part of the AIMS-2-TRIALS consortium, working with researchers to provide community perspectives and input at different stages of the research process. More information on this group can be found elsewhere on our website.

Event attendees included Members of the European Parliament (MEPs), representatives from autism organisations, autism community members and researchers also heard from MEPs from the European Parliament Disability Intergroup. The focus was on the required action that is needed for autistic people across Europe – to address and respect the rights of autistic people and to improve service access and experiences for autistic people. The event resulted in commitments from MEPs to call for an EU-wide autism strategy and highlighted new research. The event illustrated the need for a ‘common approach’ to autism at the EU level in line with a 2024 mission letter from the president of the EU commission.

Research led by the University of Cambridge, and presented by Dr Siti Nurnadhirah Binte Mohd Ikhsan, showed that autistic people across Europe experience inconsistent access to service, long waiting times and barriers to access. In terms of priorities for change, autistic people and parents of autistic people in our Europe-wide survey prioritised education, employment, public awareness and understanding of autism, public funding for autism related services, and mental healthcare.

Professor Eva Loth, from King’s College London, outlined three key achievements from AIMS-2-TRIALS. Firstly, creation of the world largest Research Platform of linked longitudinal multi-disciplinary studies from infancy to adulthood, using cutting-edge neurotechnologies, and development of new analytic tools. Secondly, establishing a Europe-wide Clinical Trials Network (including a range of rare genetic conditions linked to autism), which will enable, for example, more efficient trials of treatments of epilepsy, rare conditions associated with autism and mental health difficulties. Thirdly and most importantly, creation of a truly collaborative, inter-disciplinary research community, that includes autistic people with lived experience. This has proven to be the key to addressing needs and priorities from autistic communities and shifting from deficit frameworks to neurodiversity-affirmative research. She also highlighted that while the EU-funding for AIMS-2-TRIALS is unprecedented, it must not remain a single large-scale investment as research funding for autism and neurodevelopmental conditions is still several magnitudes smaller than that for other mental health or medical conditions.

Professor Celso Arango, from Hospital Universitario Gregorio Marañón in Madrid, shared results from the value of treatment study on care pathways for autism and co-occurring epilepsy. Strikingly, this study found that 40-50% of participants waited around 2 years for an autism diagnosis in the UK, Spain and Italy. Their research also highlighted a lack of recognition of the common co-occurrence of epilepsy with autism and the need to screen for this to improve health outcomes for autistic people.

Mr Pierre Violland, AIMS-2-TRIALS A-Rep and Professional Peer Practitioner, discussed the diversity of autism and the need for a thoughtful and inclusive approach to better understand diversity and meet the needs of autistic people. He highlighted the need for more awareness about the co-occurrence of epilepsy with autism and recommended that actions were needed to reduce delays in diagnosis, increase support for families, and reduce the economic inequalities in accessing diagnoses and other necessary support or services.

Professor Emily Jones, from Birkbeck University of London, spoke on the need to focus future research on underrepresented groups, including those with high support needs and co-occurring mental and physical health conditions. She called for more research in early intervention to better understand how to support autistic people. She also highlighted the need for further focus on sensory differences and improvements to mental health support as areas of priority for treatment for autistic people.

The event attendees were welcomed and heard from MEPs from the European Parliament Disability Intergroup Other presenters included Harald Neerland, the President of Autism-Europe; Adam Harris from AsIAm (Ireland’s autism charity), who called for a clear and dedicated autism strategy at the EU level; and Inmaculada Placencia Porrero, Senior Expert in Disability and Inclusion at the European Commission and member of the UN CRPD Committee. The event was concluded with a Q&A and panel discussion including members of the audience.

If you would like more information about this event or the research findings presented, you can find details at the links below:

• The full program of the event can be seen here.
• Watch the recording here: https://youtu.be/5k0UAzaYyQQ
• Further information on the event can be found here on the Autism Europe website here
• Summary reports of the mentioned research projects can be seen on the AIMS-2-TRIALS Autism Policies page here